Canada Nephrology and Urology Devices Market Outlook to 2023-Incontinence Devices, Lithotripters and Renal Dialysis Equipment
Region:North America
Product Code:GDMEMC0270DB
August 2017
138
About the Report
Canada Nephrology and Urology Devices Market Outlook to 2023-Incontinence Devices, Lithotripters and Renal Dialysis Equipment
Summary
GlobalData's new report, "Canada Nephrology and Urology Market Outlook to 2023", provides key market data on the Canada Nephrology and Urology market. The report provides value, in millions of US dollars and volume (in units) within market categories-Incontinence Devices, Lithotripters and Renal Dialysis Equipment.
The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
Market size and company share data for Nephrology and Urology market categories-Incontinence Devices, Lithotripters and Renal Dialysis Equipment.
Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
2016 company shares and distribution shares data for each of the market categories.
Global corporate-level profiles of key companies operating within the Canada Nephrology and Urology market.
Key players covered include Kimberly-Clark Corporation, Baxter International Inc, Medtronic plc, Cardinal Health Inc, First Quality Enterprises Inc, Fresenius Medical Care AG & Co KGaA, Svenska Cellulosa Aktiebolaget, C. R. Bard Inc, Asahi Kasei Corp, Teleflex Inc, W. L. Gore & Associates Inc, Ontex Group N.V. and others
Reasons to buy
Develop business strategies by identifying the key market categories poised for strong growth in the future.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.
Scope of the Report
Products
Companies
Medtronic Plc
Baxter International Inc
C. R. Bard Inc
Cardinal Health Inc
Fresenius Medical Care AG & Co KGaA
First Quality Enterprises Inc
Svenska Cellulosa Aktiebolaget
AngioDynamics Inc
Teleflex Inc
Ontex Group N.V.
Coloplast A/S
ConvaTec Group Plc
Hollister Incorporated
Kawasumi Laboratories Inc
NxStage Medical Inc
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Nephrology and Urology Devices Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Nephrology and Urology Devices Market, Canada 11
3.1 Nephrology and Urology Devices Market, Canada, Revenue ($m), 2009-2023 11
3.2 Nephrology and Urology Devices Market, Canada, Revenue Mix ($m), 2016 13
3.3 Nephrology and Urology Devices Market, Canada, Category Contribution by Revenue ($m), 2016 14
3.4 Nephrology and Urology Devices Market, Canada, Category Comparison by Revenue ($m), 2009-2023 15
3.5 Nephrology and Urology Devices Market, Canada, Revenue ($m), 2009-2016 16
3.6 Nephrology and Urology Devices Market, Canada, Revenue ($m), 2016-2023 18
3.7 Nephrology and Urology Devices Market, Canada, Volume (Units), 2009-2023 20
3.8 Nephrology and Urology Devices Market, Canada, Volume (Units), 2009-2016 21
3.9 Nephrology and Urology Devices Market, Canada, Volume (Units), 2016-2023 23
3.10 Nephrology and Urology Devices Market, Canada, Company Share by Revenue ($m), 2016 25
4 Incontinence Devices Market, Canada 27
4.1 Incontinence Devices Market, Canada, Revenue Mix ($m), 2016 27
4.2 Incontinence Devices Market, Canada, Segment Contribution (%), 2016 28
4.3 Incontinence Devices Market, Canada, Revenue ($m), 2009-2016 30
4.4 Incontinence Devices Market, Canada, Revenue ($m), 2016-2023 32
4.4.1 Protective Garments for Incontinence Market, Canada, Revenue ($m), by Segment, 2009-2016 34
4.4.2 Urinary Catheters Market, Canada, Revenue ($m), by Segment, 2009-2016 36
4.4.3 Protective Garments for Incontinence Market, Canada, Revenue ($m), by Segment, 2016-2023 38
4.4.4 Urinary Catheters Market, Canada, Revenue ($m), by Segment, 2016-2023 40
4.5 Incontinence Devices Market, Canada, Volume (Units), 2009-2016 42
4.6 Incontinence Devices Market, Canada, Volume (Units), 2016-2023 44
4.4.1 Protective Garments for Incontinence Market, Canada, Volume (Units), by Segment, 2009-2016 46
4.4.2 Urinary Catheters Market, Canada, Volume (Units), by Segment, 2009-2016 48
4.4.3 Protective Garments for Incontinence Market, Canada, Volume (Units), by Segment, 2016-2023 50
4.4.4 Urinary Catheters Market, Canada, Volume (Units), by Segment, 2016-2023 52
4.7 Incontinence Devices Market, Canada, Distribution Share by Revenue ($m), 2015-2016 54
4.8 Incontinence Devices Market, Canada, Company Share by Revenue ($m), 2016 55
5 Lithotripters Market, Canada 57
5.1 Lithotripters Market, Canada, Revenue Mix ($m), 2016 57
5.2 Lithotripters Market, Canada, Segment Contribution (%), 2016 58
5.3 Lithotripters Market, Canada, Revenue ($m), 2009-2016 59
5.4 Lithotripters Market, Canada, Revenue ($m), 2016-2023 61
5.5 Lithotripters Market, Canada, Volume (Units), 2009-2016 63
5.6 Lithotripters Market, Canada, Volume (Units), 2016-2023 65
5.7 Lithotripters Market, Canada, Distribution Share by Revenue ($m), 2015-2016 67
5.8 Lithotripters Market, Canada, Company Share by Revenue ($m), 2016 68
6 Renal Dialysis Equipment Market, Canada 70
6.1 Renal Dialysis Equipment Market, Canada, Revenue Mix ($m), 2016 70
6.2 Renal Dialysis Equipment Market, Canada, Segment Contribution (%), 2016 71
6.3 Renal Dialysis Equipment Market, Canada, Revenue ($m), 2009-2016 73
6.4 Renal Dialysis Equipment Market, Canada, Revenue ($m), 2016-2023 75
6.4.1 Dialysis Accessories Market, Canada, Revenue ($m), by Segment, 2009-2016 77
6.4.2 Hemodialysis Machines Market, Canada, Revenue ($m), by Segment, 2009-2016 79
6.4.3 Dialysis Accessories Market, Canada, Revenue ($m), by Segment, 2016-2023 81
6.4.4 Hemodialysis Machines Market, Canada, Revenue ($m), by Segment, 2016-2023 83
6.5 Renal Dialysis Equipment Market, Canada, Volume (Units), 2009-2016 85
6.6 Renal Dialysis Equipment Market, Canada, Volume (Units), 2016-2023 87
6.6.1 Dialysis Accessories Market, Canada, Volume (Units), by Segment, 2009-2016 89
6.6.2 Hemodialysis Machines Market, Canada, Volume (Units), by Segment, 2009-2016 91
6.6.3 Dialysis Accessories Market, Canada, Volume (Units), by Segment, 2016-2023 93
6.6.4 Hemodialysis Machines Market, Canada, Volume (Units), by Segment, 2016-2023 95
6.7 Renal Dialysis Equipment Market, Canada, Distribution Share by Revenue ($m), 2015-2016 97
6.8 Renal Dialysis Equipment Market, Canada, Company Share by Revenue ($m), 2016 98
7 Overview of Key Companies in Canada, Nephrology and Urology Devices Market 100
7.1 Medtronic Plc 100
7.1.1 Company Overview 100
7.2 Baxter International Inc 100
7.2.1 Company Overview 100
7.3 C. R. Bard Inc 100
7.3.1 Company Overview 100
7.4 Cardinal Health Inc 101
7.4.1 Company Overview 101
7.5 Fresenius Medical Care AG & Co KGaA 101
7.5.1 Company Overview 101
7.6 First Quality Enterprises Inc 101
7.6.1 Company Overview 101
7.7 Svenska Cellulosa Aktiebolaget 101
7.7.1 Company Overview 101
7.8 AngioDynamics Inc 102
7.8.1 Company Overview 102
7.9 Teleflex Inc 102
7.9.1 Company Overview 102
7.10 Ontex Group N.V. 102
7.10.1 Company Overview 102
7.11 Coloplast A/S 102
7.11.1 Company Overview 102
7.12 ConvaTec Group Plc 103
7.12.1 Company Overview 103
7.12 Hollister Incorporated 103
7.12.1 Company Overview 103
7.13 Kawasumi Laboratories Inc 103
7.13.1 Company Overview 103
7.14 NxStage Medical Inc 103
7.14.1 Company Overview 103
8 Nephrology and Urology Devices Market Pipeline Products 104
9 Financial Deals Landscape 106
9.1 Acquisition 106
9.1.1 Patricia Industries Acquires Majority Stake in Laborie Medical Technologies from Audax Private Equity 106
9.2 Equity Offerings 108
9.2.1 Kane Biotech Raises USD3 Million in Private Placement of Units 108
9.2.2 Covalon Tech Raises USD1.7 Million in Private Placement of Units 109
9.2.3 Covalon Tech Raise USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 110
9.2.4 Covalon Tech Raises USD0.8 Million in Private Placement of Shares upon Exercise of Warrants 111
9.3 Partnerships 112
9.3.1 Smartwise Enters into Licensing Agreement with Bactiguard 112
10 Recent Developments 113
10.1 Corporate Communications 113
10.1.1 Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults 113
10.1.2 Jul 05, 2017: EQL Pharma: Positive News Concerning the Pharmaceutical Product Eletriptan 114
10.1.3 Mar 24, 2017: Profound Medical announces resignation of president and COO 115
10.1.4 Dec 05, 2016: Spectral Medical appoints new board member 115
10.1.5 Oct 27, 2016: Liam J. Hurley, M.D. FACS Joins Imagin Medical's Scientific Board of Advisors 115
10.1.6 Oct 14, 2016: FDA Approves Genentech's Lucentis (Ranibizumab Injection) Prefilled Syringe 115
10.1.7 Sep 29, 2016: Ken Daignault Joins Imagin Medical's Board of Directors 116
10.1.8 Sep 22, 2016: Dr. Edward Messing, Chief of Urology, U Rochester Medical Center Joins Imagin Medical's Scientific Board of Advisors 117
10.2 Financial Announcements 117
10.2.1 May 29, 2017: Covalon Releases Second Quarter Financial Results 117
10.2.2 May 17, 2017: Kane Biotech-Q1 2017 Financial Reports 118
10.2.3 May 12, 2017: Spectral Announces First Quarter Results 118
10.2.4 Apr 26, 2017: CRH Medical Increases Total Revenue and Total Operating EBITDA by 63% During the First Quarter of 2017 118
10.2.5 Mar 30, 2017: Spectral Announces Fourth Quarter and Fiscal 2016 Results 120
10.2.6 Feb 28, 2017: Results for the second quarter of Fiscal year 2017-Ergoresearch reports its results for the quarter ended December 31, 2016 120
10.2.7 Feb 22, 2017: CRH Medical Announces 2016 Fourth Quarter and Year-end Results 121
10.2.8 Jan 30, 2017: Covalon Posts Record First Quarter Financial Results 123
10.2.9 Nov 28, 2016: Results for the first quarter of Fiscal year 2017-Ergoresearch reports its results for the quarter ended 123
10.2.10 Nov 28, 2016: Ergoresearch reports its results for the quarter ended September 30, 2016 124
10.2.11 Nov 11, 2016: Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results 124
10.2.12 Oct 28, 2016: Results for the fourth quarter and the fiscal year ended June 30, 2016-Ergoresearch reports its 2016 annual results 125
10.2.13 Oct 27, 2016: CRH Medical Announces Third Quarter 2016 Results 126
10.2.14 Oct 14, 2016: LLTECH Records Major Progress in Prostate Cancer Detection and Diagnosis on Use Its Cellular-Scale Imaging Solution 127
10.2.15 Oct 13, 2016: CARESTREAM Touch Prime XE Ultrasound System Receives Health Canada License 128
10.2.16 Oct 13, 2016: Data Demonstrating Clinical Value of Veracyte Genomic Test for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016 129
10.2.17 Aug 19, 2016: Covalon Announces Third Quarter Financial Results 129
10.2.18 Aug 12, 2016: Spectral Announces Second Quarter Results 130
10.3 Legal And Regulatory 130
10.3.1 May 23, 2017: KARL STORZ Wins Inter Partes Review Trial Invalidating Novadaq Patent 130
10.4 Other Significant Developments 131
10.4.1 Jan 23, 2017: EDAP to Exclusively Distribute LABORIE's Medical Measurement Systems 131
10.4.2 Jan 03, 2017: Covalon CEO Provides Update on Anticipated Fiscal 2017 Financial Growth 131
10.5 Product News 132
10.5.1 May 03, 2017: Covalon to Exhibit at the 2017 European Wound Management Association's Annual Conference 132
11 Appendix 134
11.1 Research Methodology 135
11.1.1 Coverage 135
11.1.2 Secondary Research 135
11.1.3 Primary Research 136
11.1.4 Company Share Analysis 136
11.1.5 Distribution Share Analysis 136
11.1.6 Benchmarking 137
11.2 GlobalData Consulting 137
11.3 Contact Us 138
11.4 Disclaimer 138
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.